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A fluid-based Papanicolaou test has been established to improve sample collection and preparation. This study was the first large-
scale investigation in Japan to examine the feasibility of using fluid-based Papanicolaou specimens to detect human papillomavirus
(HPV) using Hybrid Capture II and polymerase chain reaction (PCR). Three thousand patients who visited Keio University Hospital
between October 2000 and February 2001 were enrolled in the study. The results of the fluid-based Papanicolaou tests
corresponded well with those of conventional Papanicolaou smears (96.8% concordance). The sensitivities of cervical neoplasia
detection using the fluid-based Papanicolaou test (73.9%) and Hybrid Capture II (76.3%, P¼0.55) were not significantly different.
Among the cervical intraepithelial neoplasia 3 and squamous cell carcinoma specimens, HPV 16 and HPV 52 were predominantly
detected using the PCR method. Although some DNA samples extracted from the fluid-based specimens were degradaded, PCR
and direct sequencing could be performed without difficulty even after 1 year of specimen storage. We conclude that fluid-based
Papanicolaou specimens can be applied to investigate HPV infection.
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The fluid-based Papanicolaou specimen collection method is
widely used for primary cervical cancer screening (Awen et al,
1994; Roberts et al, 1997; Bolick and Hellman, 1998), largely
because of the improvement in specimen quality, the advantage of
increased sensitivity, and a reduction in the false negative rate for
squamous intraepithelial lesions (Linder and Zahniser, 1997; Park
et al, 2001), compared to the conventional Papanicolaou smear
method. Fluid-based specimens can be stored at ambient
temperature for a longer period; therefore, this collection system
offers the advantage that once the specimen has been collected,
there is no need to collect additional specimens from the patient to
perform a second Papanicolaou test or conduct further investiga-
tions. Studies evaluating the clinical utility of Hybrid Capture II
(HC II) human papillomavirus (HPV)-DNA testing have also been
performed (Clavel et al, 1998; Lin CT et al, 2000a; Yamazaki et al,
2001; Castle et al, 2002). Genital HPV has been reported to be
related to cervical cancer carcinogenesis and some types of HPV;
HPV 16, for example, is associated with a high risk of cervical
neoplasia (Josefsson et al, 2000; Woodman et al, 2001). HC II is a
HPV detection test designed to detect 18 types of HPV using
microtitre plates and is an appropriate method for HPV screening.
We performed the HC II test using fluid-based specimens from
patients in whom biopsy studies were also performed to determine
whether this method is appropriate for detecting cervical neoplasia
in Japan. We also performed HPV typing using fluid-based
specimens. We previously reported an HPV-DNA transcript
detection method using cytologic specimens and reverse tran-
scriptase-nested polymerase chain reactions (PCR) (Fujii et al,
1995), and a method for detecting multiplex HPV infection using
PCR single-stranded DNA-conformational polymorphism analysis
(Nakagawa et al, 2002). We applied these methods to the fluid-
based specimens and then performed direct sequencing of the PCR
products.
HPV testing with PCR using fluid-based specimens, in
conjunction with cytologic and biopsy follow-up, has been
reported to be useful for estimating the significance of atypical
squamous cells of undetermined significance (Crum et al, 1999),
and the concordance rate of HC II and PCR has been reported
to be approximately 90% for fluid-based specimens (Peyton
et al, 1998). HPV screening with HC II and HPV-typing analysis
can be performed using residual specimens without the need
to collect a second specimen from the patient; this collection
system is thus of great advantage to both patients and clinicians.
To our knowledge, however, the feasibility of using the fluid-
based Papanicolaou test in conjunction with HPV testing
has not been examined in Japan. Japan has more than 5000
cytotechnologists, and cytology has been established as an
independent method of screening for cervical neoplasia. This
study is the first large-scale investigation in Japan to examine
the utility of fluid-based Papanicolaou specimens. In addition, the
storage conditions for fluid-based specimens are controversial,
and some of the genomic DNA was degraded in the samples that
we examined. Therefore, we also investigated the quality of the
genomic DNA in the specimens. This study was undertaken
to evaluate the feasibility of using fluid-based Papanicolaou
specimens to detect HPV using both the HC II and PCR methods
in Japan.
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Three thousand patients who visited our clinic between October
2000 and February 2001 were enrolled in the study. The patient
population consisted of a mixture of asymptomatic women and
those who were being followed-up for previous atypical smears or
the treatment of previous genital malignancies. Cervical samples
were collected using both the conventional method and the
ThinPrep method, simultaneously. The conventional smears were
collected with a survexbrush and fixed in ethanol at the time of
collection. The ThinPrep samples were collected using the
ThinPrep Cytology Collection System (Cytyc Corporation, Box-
borough, USA), according to the manufacturer’s directions. Out of
the 3000 cases, colposcopy and biopsy studies were performed in
557 patients. The ThinPrep sample vials were stored at ambient
temperature and used for the HPV-DNA analysis within 12 months
of collection. Specimens from 477 random patients in whom
biopsy studies had also been performed were subjected to HPV-
DNA detection using HC II (Digene Inc., Silver Spring, USA), while
specimens from 146 random cases diagnosed as having cervical
neoplasia on the basis of biopsy studies were subjected to HPV-
DNA detection using PCR. The HC II and PCR test results were
compared in 133 cases. HPV typing and sequencing analysis were
performed in all the PCR-positive cases. Informed consent was
obtained from each biopsy study participant after an oral
explanation of the study.
Fluid-based cervical cytology
Thin-layer slides were prepared using the ThinPrep 2000 Auto-
mated Slide Processor (Cytyc Corp., Boxborough, USA), according
to the manufacturer’s instructions. Briefly, the vial containing the
cells was placed in the processor, and a dispersion cycle
homogenised the cell suspension. The cells were then automati-
cally collected on a polycarbonate filter membrane. A thin, evenly
dispersed monolayer of cells was deposited from the filter onto the
slide in a circle with a diameter of 20mm. Extraneous mucus and
blood were removed in the process. The slides were then manually
removed from the processor and stained using the Papanicolaou
method. All slides, both conventional and ThinPrep, were screened
by three cytotechnologists (MS, HT, and YN). The diagnostic
adequacy of the fluid-based Papanicolaou specimens was com-
pared with those of both conventional Papanicolaou smear and
biopsy specimens.
HPV detection using HC II
HPV-DNA detection was performed using the commercially
available HC II hybrid capture technique. Fluid-based specimens
were analysed for the presence of low-risk HPV types 6, 11, 42, 43,
and 44 using a Probe A cocktail, and for high-risk HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 using a Probe B
cocktail. The sensitivity of the HC II method for detecting cervical
neoplasia was then compared with that of the ThinPrep slides. The
enzyme-linked immunosorbent assay was based on a sandwich
hybridisation followed by a nonradioactive alkaline phosphatase
reaction with chemiluminescence on microplates.
DNA extraction
Approximately 10ml of preserved fluid was centrifuged at
3000r.p.m. for 30min. The pellet was washed once in phosphate-
buffered saline, followed by genomic DNA extraction using
proteinase K and phenol–chloroform treatment. The quality and
quantity of the extracted genomic DNA were monitored using
ethidium bromide-stained agarose gel electrophoresis.
Polymerase chain reaction
The presence of intracellular HPV DNA was determined using PCR
analysis with consensus primer pairs (L1C1, L1C2) (Yoshikawa
et al, 1991), designed to amplify an approximately 250-bp segment
of DNA. These consensus primer pairs target the HPV L1 open
reading frame and detect a broad range of genital HPVs. A 50ml
volume containing 20mM Tris HCl buffer (pH 8.0), 50mM KCl,
0.2mM dNTP mix, 2mM MgCl2, 0.5mM of each forward and reverse
primer, and 0.25U of Taq polymerase (TaKaRa, Otsu, Japan) was
used for each reaction. After an initial period of denaturation at
951C for 10min, 43 cycles of reactions were performed, each
consisting of denaturation at 951C for 1.5min, annealing at 481C
for 1.5min, and extension at 701C for 2min. PK114/K, a variant
HPV16 clone provided by Dr Mattias Durst, was used as a positive
control.
Direct sequencing of PCR products
A partial L1 sequence was amplified by the primer L1C1. The
amplified PCR products were purified, and automated sequencing
was performed using an ABI Prism 3100 Genetic Analyser (Applied
Biosystems, Foster City, CA, USA). The HPV type was determined
based on an approximately 200 bases of L1 sequence and a search
of the NCBI database (GenBank sequences; http://www.ncbi.nlm.
nih.gov/blast/Blast.cgi) using Sequencing Analysis 3.3 software
(The Perkin–Elmer Corporation, Norwalk, CT, USA).
Statistics
Correlations in sensitivity between the ThinPrep slide and
conventional Papanicolaou smear tests for the detection of cervical
neoplasia and the concordance rate of each cytological method
with the histological results were examined using McNemar’s w
2
test. Correlations in sensitivity between the ThinPrep slide and HC
II tests for the detection of cervical neoplasia were examined using
the w
2 test. Correlations in the concordance rate of the HC II and
PCR test results between the cases with CIN1 and those with CIN2,
CIN3, and SCC were examined using Fisher’s exact probability test.
The HPV-positive rates were also examined using Fisher’s exact
probability test. P-values of 0.05 or less were considered to be
statistically significant.
RESULTS
Cytologic studies were performed in all 3000 cases. Twelve cases of
glandular dysplasia, 11 cases of adenocarcinoma, five cases of
adenocarcinoma in situ and one case of small cell carcinoma, all
diagnosed cytologically, were excluded; the diagnostic results of
the ThinPrep slide and conventional Papanicolaou smear speci-
mens were then compared in the remaining 2971 cases (Table 1).
Table 1 Diagnosis of ThinPrep slides and conventional smears
Conventional
ThinPrep Neg BA LGSIL HGSIL SCC Total
Neg 2579 9 18 0 0 2606
BA 3 16 4 2 0 25
LGSIL 17 3 151 21 0 192
HGSIL 2 0 12 106 4 124
SCC 0 0 0 0 24 24
Total 2601 28 185 129 28 2971
Neg¼negative slide or smear; BA¼benign atypia; LGSIL¼low-grade squamous
intraepithelial lesion; HGSIL¼high-grade squamous intraepithelial lesion;
SCC¼squamous cell carcinoma.
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yThese 2971 cases consisted of patients with negative findings,
benign atypia, low-grade squamous intraepithelial lesions, high-
grade squamous intraepithelial lesions (HGSIL), or squamous cell
carcinoma (SCC), based on their Papanicolaou test results. The
concordance rate between the fluid-based Papanicolaou test results
and the conventional Papanicolaou smear results was high (96.8%,
2876 out of 2971 cases). The percentage of cases with benign atypia
did not differ significantly between the ThinPrep slide results
(0.8%, 25 out of 2971 cases) and the conventional Papanicolaou
smear results (0.9%, 28 out of 2971 cases, P¼0.66).
Biopsy studies were performed in 557 of the 3000 cases. Based
on the histological diagnosis, five cases of adenocarcinoma, five
cases of adenocarcinoma in situ, three cases of condyloma
acuminatum, two cases of adenosquamous cell carcinoma, and
one case of small cell carcinoma were excluded from the 557 cases.
A comparison between the cytological and histological results for
the remaining 541 cases is shown in Tables 2 and 3. The absolute
concordance rate between the cytological and histological results
was 73.9% (400 out of 541 cases) for the fluid-based Papanicolaou
test and 73.2% (396 of 541 cases) for the conventional
Papanicolaou smear. This difference was not significant
(P¼0.12). The detection sensitivities for cervical intraepithelial
neoplasia1 (CIN1), CIN2, CIN3, and SCC were 53.2, 81.5, 94.3, and
100.0%, respectively, for the ThinPrep slides, and 55.3, 83.3, 96.2,
and 100.0%, respectively, for the conventional Papanicolaou smear
specimens. These differences were not significant for any
histological category (P40.4). In the same manner, the CIN and
SCC detection sensitivities also did not differ between the
ThinPrep slides (73.9%, 161 out of 218 cases) and the conventional
Papanicolaou smear specimens (75.7%, 165 out of 218 cases,
P¼0.22).
An HC II analysis was randomly performed in 477 of the 541
cases who underwent biopsy studies. Only cases positive for high-
risk HPV were regarded as positive in this study; cases positive for
only low-risk HPV were regarded as negative. The sensitivity of HC
II for detecting CIN1, CIN2, CIN3, and SCC was 59.1% (55 out of
93 cases), 84.9% (45 out of 53 cases), 90.6% (48 out of 53 cases),
and 100.0% (16 out of 16 cases), respectively. The overall CIN and
SCC detection sensitivities did not differ significantly between the
HC II (76.3%, 164 out of 215 cases) and the ThinPrep slide (73.9%,
161 out of 218 cases, P¼0.56) test results.
Table 4 summarises the HPV-positive rates as detected using
direct sequencing of the PCR products. Fisher’s exact probability
test revealed that the frequency of cases with CIN3 or SCC,
compared to those with CIN1 or CIN2, in the HPV 16-positive
cases (67.6%, 25 out of 37 cases) or HPV 52-positive cases (62.5%,
10 out of 16 cases) was significantly higher than that of the other
HPV types (19.4%, 12 out of 62 cases, P o 0.00001 for HPV 16, P
o 0.01 for HPV 52). We also found that the frequency of cases
with adenocarcionoma or adenocarcinoma in situ, compared to
those with CIN or SCC, in the HPV 18-positive cases (30.8%, four
out of 13 cases) was higher than that of the other HPV types (0.9%,
one out of 107 cases, P o 0.001). HPV 18 was also detected in one
case of the adenosquamous cell carcinoma.
The concordance rate between the HC II and PCR test results
was 68.1% (32 out of 47 cases) in cases with CIN1, 88.4% (76 out of
86 cases) in cases with CIN2, CIN3, or SCC, and 81.2% (108 out of
133 cases) overall (Table 5). The concordance rate between test
Table 2 Comparison between histological and conventional cytological
diagnosis
Histological diagnosis
Conventional CC CIN1 CIN2 CIN3 SCC Total
Neg 262 40 7 0 0 309
BA 8 2 2 1 0 13
LGSIL 41 40 14 2 0 97
HGSIL 12 12 31 43 1 99
SCC 0 0 0 6 16 22
Total 323 94 54 53 17 541
Neg¼negative slide or smear; BA¼benign atypia; LGSIL¼low-grade squamous
intraepithelial lesion; HGSIL¼high-grade squamous intraepithelial lesion; CC¼
chronic cervicitis; CIN¼cervical intraepithelial neoplasia; SCC¼squamous cell
carcinoma.
Table 4 Positive rate of HPV by PCR
Infection of HPV–(type of HPV)
Histological diaganosis Overall HPV 16 HPV 52 Others HPV 18 Others
CIN1 37/51 (72.5%) 4 (7.8%) 2 (3.9%) 31 (60.8%) 1 (2.0%) 36 (70.6%)
CIN2 31/33 (93.9%) 8 (24.2%) 4 (12.1%) 19 (57.6%) 5 (15.2%) 26 (78.8%)
CIN3 35/41 (85.4%) 19 (46.3%) 9 (22.0%) 7 (17.1%) 1 (2.4%) 34 (82.9%)
SCC 12/14 (85.7%) 6 (42.9%) 1 (7.1%) 5 (35.7%) 2 (14.3%) 10 (71.4%)
AIS 2/3 (66.7%) 0 (0%) 0 (0%) 2 (66.7%) 1 (33.3%) 1 (33.3%)
AC 3/3 (100%) 0 (0%) 0 (0%) 3 (100%) 3 (100%) 0 (0%)
ASC 1/1 (100%) 0 (0%) 0 (0%) 1 (100%) 1 (100%) 0 (0%)
*Po0.00001 **Po0.01 ***Po0.001
CIN¼cervical intraepithelial neoplasia; SCC¼squamous cell carcinoma; AIS¼adenocarcinoma in situ;
AC¼adenocarcinoma; ASC¼adenosquamous cell carcinoma. *Fisher’s exact probability test for positivity of HPV 16 vs
others between CIN1–CIN2 and CIN3–SCC. **Fisher’s exact probability test for positivity of HPV 52 vs others between
CIN1–CIN2 and CIN3–SCC. ***Fisher’s exact probability test for positivity of HPV 18 vs others between CIN1–SCC and
AIS–AC.
Table 3 Comparison between histological and ThinPrep cytological
diagnosis
Histological diagnosis
ThinPrep CC CIN1 CIN2 CIN3 SCC Total
Neg 264 42 7 2 0 315
BA 6 2 3 1 0 12
LGSIL 41 40 15 3 0 99
HGSIL 12 10 29 43 3 97
SCC 0 0 0 4 14 18
Total 323 94 54 53 17 541
Neg¼negative slide or smear; BA¼benign atypia; LGSIL¼low-grade squamous
intraepithelial lesion; HGSIL¼high-grade squamous intraepithelial lesion; CC¼
chronic cervicitis; CIN¼cervical intraepithelial neoplasia; SCC¼squamous cell
carcinoma.
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yresults for cases with CIN2, CIN3, and SCC was higher than that for
cases with CIN1 (Po0.01).
While performing the PCR analyses, we found that some DNA
samples extracted from the fluid-based specimens were degra-
daded when examined by electrophoresis. We analysed 170
samples in which the yield of the extracted DNA was more than
5mg in total. We then categorised the extracted DNA samples
into grade 1, grade 2, or grade 3 degradation (Figure 1). DNA
samples containing fragments mainly larger than 2kb were
classified as grade 1 degradation. DNA samples containing
1–2kb fragments were classified as grade 2 degradation. DNA
samples containing fragments smaller than 1kb were classified
as grade 3 degradation. Grade 1, grade 2, and grade 3 degradation
were seen in 96 cases (56%), 51 cases (30%), and 23 cases (14%),
respectively. Although the positive bands for PCR products from
a given genomic DNA with grade 1 or grade 2 degradation were
clear, those from genomic DNA with grade 3 degradation were
not because the degraded genomic DNA masked the PCR products.
However, positive bands could be detected in all of the samples
(Figure 2). Consequently, PCR and direct sequencing was
successfully performed in all the DNA samples, even after
some of the samples had been stored for 12 months, although
some DNA samples extracted from the fluid-based specimens had
degraded.
DISCUSSION
In this report, we performed the first large-scale study in Japan to
examine the use of a new fluid-based Papanicolaou specimen
collection system in 3000 Japanese women; the results were then
compared to those of conventional smears. We also evaluated the
use of residual fluid-based specimens after long-term storage in
several molecular analyses, such as HPV screening by HC II, HPV
detection by PCR, and HPV typing by sequencing.
The ThinPrep 2000 fluid-based, thin layer automated slide
preparation system was designed to improve sample collection and
preparation. Since fluid-based specimens can be stored at ambient
temperatures for more than 1 year, this collection system is
advantageous in that the Papanicolaou specimen can be re-
examined several times using the residual specimen after the initial
Papanicolaou test has been performed. In addition, this collection
system makes it possible to perform follow-up studies without
unduly inconveniencing the patient.
Several studies have reported that molecular analyses can be
performed using fluid-based specimens and that these specimens
enable the integrity of cellular DNA, RNA, and proteins to be
retained (Lin WM et al, 2000b; Tarkowski et al, 2001). Therefore,
molecular analyses can be performed using the residual specimen
after a cytological diagnosis has been made, without the need to
collect a second specimen from the patient. To our knowledge,
however, the use of fluid-based Papanicolaou test specimens for
HPV detection has not been reported in Japan.
This study of 3000 patients demonstrated that the quality of
fluid-based ThinPrep slides is similar to that of conventional
Papanicolaou smears, with regard to their use in screening and
cervical neoplasia detection. Our results revealed a high con-
cordance rate between the ThinPrep slide and conventional
Papanicolaou smear test results. The CIN and SCC detection
sensitivities and the percentage of cases with benign atypia did not
differ between the two methods. However, some studies in Europe
and America have reported an increased sensitivity for the
detection of cervical neoplasia using the ThinPrep slide method
(Awen et al, 1994; Linder and Zahniser, 1997; Roberts et al, 1997;
Papillo et al, 1998). Other studies have reported that the rate of
atypical squamous cells of undetermined significance decreased
with the use of ThinPrep slides (Bolick and Hellman, 1998; Park
Table 5 Comparison between HC II and PCR for the detection of high-
risk HPV DNA
CIN1 CIN2, CIN3, and SCC
HC II HC II
(+) ( ) (+) ( )
PCR (+) 20 13 72 4
( )2 1 2 6 4
CIN¼cervical intraepithelial neoplasia; SCC¼squamous cell carcinoma.
Figure 1 Estimating the quality of the extracted genomic DNA.
Genomic DNA was electrophoresed on a 0.8% agarose gel. The quality
of the extracted genomic DNA was classified into three categories.
Genomic DNA samples 1, 2, 4, 6, 7, 9, 12, and 13 were classified as
exhibiting grade 1 degradation. Genomic DNA samples 3, 5, 8, and 10
were classified as exhibiting grade 2 degradation. Genomic DNA sample 11
was classified as exhibiting grade 3 degradation. M shows the lDNA/HindIII
marker.
Figure 2 Detection of PCR products using electrophoresis. PCR
products were electrophoresed on a 3% agarose gel. Lane 1, PCR
products using genomic DNA with grade 1 degradation as a template; lane
2, PCR products using genomic DNA with grade 2 degradation as a
template; lanes 3, 4, and 5, PCR products using genomic DNA with grade 3
degradation as a template. M shows the 100-bp DNA ladder marker. P
shows the positive control. N shows the negative control.
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yet al, 2001). These differences are probably related to differences in
cervical neoplasia screening programmes. In Japan, more than
5000 cytotechnologists are working in this field, so cytotechnol-
ogists can spend a longer time per case than in other countries.
Although the two methods are similar in quality, we prefer the
fluid-based Papanicolaou test because fluid-based specimens can
be stored at ambient temperatures for long periods and can be
used in other ways, such as in molecular analyses.
HC II was recently reported to be a useful kit for detecting HPV
DNA (Clavel et al, 1998; Lin CT et al, 2000a; Castle et al, 2002).
Thirteen types of high-risk HPV and five types of low-risk HPV
can be detected using HC II. Ferenczy reported that the fluid-based
cytologic system provides adequate material for hybrid capture
tests (Ferenczy et al, 1996). Our results also showed that fluid-
based specimens could be used in the HC II test. The sensitivity of
HC II for detecting CIN and SCC was the same as that of the
ThinPrep slides. The sensitivity of HC II for detecting HGSIL was
also similar to previously reported values (73–93%) (Clavel et al,
1998; Kuhn et al, 2000; Lin CT et al, 2000a; Yamazaki et al, 2001).
HC II may be a useful test for detecting cervical neoplasia in
countries without cytologic screening systems. We prefer the
Papanicolaou test, however, because more information, such as the
grade of the dysplastic cells, can be obtained; the sensitivities of the
Papanicolaou and HC II tests were similar.
We found that HPV 16 and HPV 52 were the predominant HPV
types found in CIN3 and SCC, based on the direct sequencing of
PCR products; consequently, CIN cases that are positive for these
HPV types should be more strictly followed up than cases positive
for other HPV types. Yoshikawa et al (1999) reported that HPV
types 16, 18, 31, 33, 51, 52, and 58 were predominantly detected in
HGSIL. Sasagawa et al. (2001) reported that HPV types 16, 31, 33,
35, 45, 51, 52, 56, and 58 were associated with HGSIL, while HPV
types 16, 18, 31, 51, 52, and 58 were associated with SCC; thus
infection with HPV type 16, 18, 31, 51, 52, or 58 is considered to be
associated with a high-risk of CIN and SCC in Japanese women.
Our results also revealed that HPV 18 was predominantly detected
in adenocarcinoma, as previously reported (Lizano et al, 1997;
Shyu et al, 2001). We previously reported that the incidence of
multiple HPV coinfection was 38.3% in cervical dysplasia
(Nakagawa et al, 2002). The significance of multiple HPV
coinfection is controversial; therefore, our strategy for elucidating
cells with multiple HPV coinfection to be performed in the future
experiments may be useful.
The concordance rate between HC II and PCR test results has
been reported to be high (Clavel et al, 1998; Peyton et al, 1998;
Terry et al, 2001), but one study reported a rate of only 83%
(Yamazaki et al, 2001). Our concordance rate (81.2%) was similar
to that in the report by Yamazaki et al. Our study also revealed that
the concordance rate between test results in CIN1 cases (68.1%)
was lower than that in more progressive lesions (88.4%). The cause
of the lower concordance rate among CIN1 cases is probably
related to a low copy number of the HPV genome and a higher
PCR sensitivity for the detection of HPV. In addition, HPV types
that were not included in Probe B cocktail of HC II or unknown
types of HPV can be detected using the PCR method.
In conclusion, the fluid-based Papanicolaou test produces
specimens of the same quality as those produced using conven-
tional Papanicolaou smears. ThinPrep sample vials can be stored
at ambient temperature for periods of more than 1 year;
furthermore, the detection of HPV DNA can be performed using
residual specimens after cytological or biopsy studies have been
completed. Moreover, a follow-up protocol consisting of con-
current cytology and HPV-DNA detection can be performed in
patients with a high risk of CIN or SCC. This collection system
should enable significant advances in molecular epidemiology and
is useful for identifying high-risk cases of cervical cancer.
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